{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:09:32Z","timestamp":1762016972354},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1097\/01.aids.0000174451.78497.8f","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T10:55:56Z","timestamp":1118832956000},"page":"1051-1058","source":"Crossref","is-referenced-by-count":81,"title":["Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia"],"prefix":"10.1097","volume":"19","author":[{"given":"Leonardo","family":"Calza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Colangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Tampellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Pocaterra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002030-199907090-00001","article-title":"Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors","volume":"13","author":"Behrens","year":"1999","journal-title":"AIDS"},{"issue":"Suppl 1","key":"R2-10-20210130","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/00126334-200010001-00002","article-title":"Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review","volume":"25","author":"Graham","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-10-20210130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0924-8579(03)00115-8","article-title":"Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management","volume":"22","author":"Calza","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"R4-10-20210130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00075197-200103000-00003","article-title":"Hyperlipidemia and inhibitors of HIV protease","volume":"4","author":"Distler","year":"2001","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R5-10-20210130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00042560-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors indipendent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-10-20210130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/00002030-200005050-00023","article-title":"Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridemia and diabetes mellitus","volume":"14","author":"Paparizos","year":"2000","journal-title":"AIDS"},{"key":"R7-10-20210130","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200409030-00010","article-title":"Cardio- and cerebrovascular events in HIV-infected persons","volume":"18","author":"d\u2019Arminio Monforte","year":"2004","journal-title":"AIDS"},{"key":"R8-10-20210130","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","article-title":"Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men","volume":"17","author":"Mary-Krause","year":"2003","journal-title":"AIDS"},{"key":"R9-10-20210130","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-10-20210130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/dkh379","article-title":"Protease inhibitor-sparing simplified maintenance therapy: a need for perspective","volume":"54","author":"Bucher","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R11-10-20210130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/343050","article-title":"Switching effective antiretroviral therapy: a review","volume":"35","author":"Drechsler","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R12-10-20210130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","article-title":"Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047","volume":"16","author":"Fichtenbaum","year":"2002","journal-title":"AIDS"},{"key":"R13-10-20210130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","article-title":"Guidelines for the evaluation and management of dyslipidaemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group","volume":"37","author":"Dub\u00e9","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R14-10-20210130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00001432-199902000-00003","article-title":"Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome","volume":"12","author":"Martinez","year":"1999","journal-title":"Curr Opin Infect Dis"},{"key":"R15-10-20210130","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1345\/aph.18174","article-title":"Hyperlipidemia associated with protease inhibitor therapy","volume":"33","author":"Echevarria","year":"1999","journal-title":"Ann Pharmacother"},{"key":"R16-10-20210130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s15010-002-3044-7","article-title":"Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management","volume":"30","author":"Hirsch","year":"2002","journal-title":"Infection"},{"issue":"Suppl 1","key":"R17-10-20210130","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"Carr","year":"2003","journal-title":"AIDS"},{"key":"R18-10-20210130","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00002030-199811000-00024","article-title":"Marked hypertriglyceridemia associated with ritonavir therapy","volume":"12","author":"Sullivan","year":"1998","journal-title":"AIDS"},{"key":"R19-10-20210130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1056\/NEJM199809103391115","article-title":"HIV-protease inhibitors","volume":"339","author":"Di Perri","year":"1998","journal-title":"N Engl J Med"},{"key":"R20-10-20210130","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch Intern Med"},{"key":"R21-10-20210130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00126334-200003010-00009","article-title":"Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998","volume":"23","author":"Thiebaut","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-10-20210130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1086\/313995","article-title":"Coronary artery disease and human immunodeficiency virus infection","volume":"31","author":"Passalaris","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R23-10-20210130","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1006\/jmcc.2000.1271","article-title":"Atherosclerosis in AIDS: potential pathogenetic roles of antiretroviral therapy and HIV","volume":"32","author":"Lewis","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"R24-10-20210130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1749-6632.2001.tb03908.x","article-title":"Cardiology and AIDS-HAART and the consequences","volume":"946","author":"Hoffmann","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"R25-10-20210130","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/00002030-200209270-00019","article-title":"Vascular disease in HIV-infected patients: a comparative study of two different therapeutic periods (1994\u20131997 versus 1998\u20132000)","volume":"16","author":"Dronda","year":"2002","journal-title":"AIDS"},{"key":"R26-10-20210130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000067120","article-title":"Stroke in HIV-infected patients: a clinical perspective","volume":"15","author":"Rabinstein","year":"2003","journal-title":"Cerebrovasc Dis"},{"key":"R27-10-20210130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s100960050194","article-title":"Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS","volume":"17","author":"Mirete","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R28-10-20210130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R29-10-20210130","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/01.ATV.20.12.2625","article-title":"HIV protease inhibitors stimulate hepatic triglyceride synthesis","volume":"20","author":"Lenhard","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R30-10-20210130","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0002-8703(02)00135-7","article-title":"Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors","volume":"144","author":"Meng","year":"2002","journal-title":"Am Heart J"},{"key":"R31-10-20210130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0021-9150(02)00016-3","article-title":"Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: \u201ca call for cardiovascular prevention\u201d","volume":"163","author":"Acevedo","year":"2002","journal-title":"Atherosclerosis"},{"key":"R32-10-20210130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh013","article-title":"Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients","volume":"53","author":"Calza","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R33-10-20210130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"R34-10-20210130","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/00002030-200311210-00007","article-title":"Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients","volume":"17","author":"Bucher","year":"2003","journal-title":"AIDS"},{"key":"R35-10-20210130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-5-2","article-title":"Substituting abacavir for hyperlipidaemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment","volume":"5","author":"Keiser","year":"2005","journal-title":"BMC Infect Dis"},{"key":"R36-10-20210130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00126334-200305010-00005","article-title":"Randomized, controlled, 48-week study of switching stavudine and\/or protease inhibitors to combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients","volume":"33","author":"John","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-10-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R38-10-20210130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/154510970400300304","article-title":"Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials","volume":"3","author":"Cahn","year":"2004","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"R39-10-20210130","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1345\/aph.1D394","article-title":"Atazanavir","volume":"38","author":"Orrick","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R40-10-20210130","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.amjcard.2004.06.025","article-title":"Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia","volume":"94","author":"Kannel","year":"2004","journal-title":"Am J Cardiol"},{"key":"R41-10-20210130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00002030-200304110-00010","article-title":"Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART","volume":"17","author":"Calza","year":"2003","journal-title":"AIDS"},{"key":"R42-10-20210130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1468-1293.2004.00200.x","article-title":"Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999\u20132001","volume":"5","author":"Bonnet","year":"2004","journal-title":"HIV Med"},{"key":"R43-10-20210130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s15010-004-3136-7","article-title":"Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir","volume":"32","author":"Benesic","year":"2004","journal-title":"Infection"},{"key":"R44-10-20210130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s15010-001-2052-3","article-title":"Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART","volume":"30","author":"Calza","year":"2002","journal-title":"Infection"},{"key":"R45-10-20210130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jinf.2003.09.006","article-title":"Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice","volume":"49","author":"Visnegarwala","year":"2004","journal-title":"J Infect"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.aids.0000174451.78497.8f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:43:50Z","timestamp":1620935030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200507010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aids.0000174451.78497.8f","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}